How a Single Patient’s Bronchiectasis Battle Is Rewriting the Rules of Care

Bronchiectasis is one of respiratory medicine’s most stubborn adversaries, a chronic inflammatory lung disease in which the airways become permanently damaged and dilated, trapping mucus and inviting infection. Patients typically endure a relentless cycle of chronic cough, copious sputum production, and repeated respiratory infections, punctuated by acute deteriorations known as exacerbations. Now, a newly published case study in Clinical Case Reports has offered clinicians and patients alike a rare, detailed window into how these difficult exacerbations unfold in the real world, and how the latest European Respiratory Society guidelines can steer care toward better outcomes. The report follows a 75-year-old British man through nearly a year of escalating illness, revealing both the power of evidence-based medicine and the gaps that still separate guidelines from everyday practice.

The science underlying the disease is elegantly captured by what researchers call the vicious vortex, a conceptual framework building on the vicious cycle theory first proposed by Professor Peter Cole in 1986. Four interrelated factors drive the pathology: airway inflammation, impaired mucociliary clearance, airway infection, and structural lung damage. Each element feeds the others, so that infection triggers inflammation, inflammation impairs the tiny hair-like cilia that sweep mucus from the airways, stagnant secretions harbor more bacteria, and the resulting damage further distorts the airway architecture. Exacerbations accelerate this vortex. They are formally defined as a deterioration in three or more key symptoms lasting at least 48 hours, including cough, sputum volume or purulence, breathlessness, fatigue, or coughing up blood, alongside a clinician’s judgment that treatment must change. Each episode is associated with declining lung function, diminished quality of life, and increased mortality, and a history of exacerbations is itself a major predictor of future ones.

The patient at the heart of the case study illustrates just how formidable this vortex can become. Diagnosed with bronchiectasis in 2005 at age 55, he also carries diagnoses of asthma and chronic obstructive pulmonary disease, and he is an ex-smoker with 20 pack-years of history. Serial CT scans reveal extensive bilateral bronchiectasis concentrated in the mid and lower zones of his lungs, and his Bronchiectasis Severity Index score of 18 places him in a high-risk category. He suffers numerous exacerbations every year, driven by the combined burden of all three chronic lung conditions. In July 2024, he noticed the familiar warning signs: coughing up large amounts of purulent sputum, worsening breathlessness, and crushing exhaustion. Recognizing an exacerbation, he did exactly what his self-management plan advised, starting a two-week course of oral co-amoxiclav from a rescue pack kept at home and provided by his general practitioner.

That early self-treatment, which the new ERS guidelines explicitly endorse, proved insufficient. When he failed to improve, his GP prescribed a further two weeks of the same antibiotic, and still his symptoms persisted. Only when he contacted his specialist hospital team was his care escalated, and here the case illuminates a crucial structural innovation in modern British healthcare: the respiratory virtual ward. Admitted to this hospital-at-home service, the patient received close monitoring from a multidisciplinary team along with hospital-level diagnostics and interventions, including the ability to self-administer intravenous treatments in his own home. The NHS launched a national virtual wards programme in 2023 aiming to expand exactly this kind of hospital-level care at home, and evidence suggests patients often prefer it, feeling more comfortable and recovering faster in familiar surroundings while health systems relieve pressure on physical beds.

The microbiology that followed reads like a detective story. Consistent with guideline recommendations, a sputum sample had been taken at the onset of the exacerbation before antibiotics began, and it grew Proteus mirabilis, a bacterium not typically associated with bronchiectasis, sensitive to co-amoxiclav, along with Candida species, which are common commensals that usually require no targeted therapy. When oral antibiotics failed, the team switched to intravenous meropenem, one gram three times daily, self-administered at home for two weeks. Research on home intravenous therapy in bronchiectasis remains limited, but retrospective studies in adults and children suggest clinical outcomes comparable to inpatient care, with the added benefits of reduced risk of hospital-acquired infection and better quality of life. Remarkably, even intravenous meropenem failed to produce improvement, and the authors of the case report argue that the problem was likely not antimicrobial resistance but inadequate airway clearance, a reminder that antibiotics alone cannot break the vicious vortex if secretions remain trapped in damaged airways.

This is where the guidelines place enormous weight on airway clearance techniques, or ACTs, such as active cycle of breathing techniques and positive expiratory pressure devices. These interventions directly target the impaired mucociliary clearance component of the vortex, improving sputum clearance, reducing the burden of cough, lowering exacerbation risk, and improving quality of life. The ERS recommends that ACTs be adapted in frequency, intensity, and technique during exacerbations, and the patient was duly referred to physiotherapy. Yet he waited several months to see a respiratory physiotherapist, a delay the authors describe as sadly reflective of real-life disparities in access across the UK. When he finally received instruction, his first device, a positive expiratory pressure mouthpiece, proved intolerable because it triggered coughing, so he was switched to an oscillating positive expiratory pressure device with a slow expiratory phase to suppress the cough reflex, used after his COPD inhaler to open the airways first. At his six-week follow-up he reported easier clearance and thinner mucus, a small technical adjustment with a meaningful clinical payoff.

The bacterial saga continued. Two weeks after discharge he was readmitted with persistently high sputum volume, and cultures now showed a heavy growth of Pseudomonas aeruginosa, a notoriously resilient pathogen in bronchiectasis. The guidelines recommend eradication treatment for any new isolation of this organism, typically two weeks of oral or intravenous antibiotics followed by six to twelve weeks of inhaled antibiotics. The patient received two weeks of home intravenous meropenem, extended by two more weeks, plus daily hospital visits for intravenous tobramycin at three milligrams per kilogram, later escalated to five after monitoring confirmed stable kidney function. Evidence for dual antimicrobial therapy against Pseudomonas in bronchiectasis is thin, but data from cystic fibrosis populations support combining a beta-lactam with an aminoglycoside for chronic infection, always balanced against the risks of kidney and ear toxicity in older patients. By December 2024, bronchoscopy revealed Pseudomonas resistant to tobramycin, colistin, and gentamicin, confirming the eradication attempt had failed, and his treatment moved to three weeks of intravenous ceftazidime at home.

With chronic Pseudomonas infection now established, the guidelines strongly recommend long-term inhaled antibiotics, and the patient’s nebulised tobramycin prophylaxis was escalated from alternating months to continuous therapy. The guidelines also strongly recommend long-term macrolides for patients at high risk of exacerbations despite standard care, and large randomized trials such as EMBRACE and BAT have demonstrated that daily azithromycin reduces exacerbation frequency, including in patients with chronic Pseudomonas. He began 500 milligrams three times weekly, but only after screening for nontuberculous mycobacterial infection, QTc prolongation on his heart rhythm tracing, and liver and kidney abnormalities, as both the ERS and British Thoracic Society guidelines demand, with repeat checks four weeks later. He has tolerated the regimen well and remains stable, with no antibiotics needed for bronchiectasis exacerbations since March 2025 and a culture-negative sputum sample in April 2025.

The case also exposes the harder edges of long-term management. Mucoactive drugs such as hypertonic saline and carbocisteine are recommended when airway clearance alone fails to control symptoms, though a recent trial found neither significantly reduced exacerbation rates, and the patient’s own experience was mixed: years of nebulised normal saline with no evidence base, a trial of seven percent hypertonic saline that only slightly thinned his sputum, and a final refusal to restart it because the treatment burden was too great. He declined further pulmonary rehabilitation despite guideline support, and his long-term inhaled corticosteroids, discouraged for bronchiectasis itself, are appropriately continued for his asthma and COPD. His vaccination record, covering influenza, COVID-19, pneumococcal disease, respiratory syncytial virus, and shingles, exemplifies the preventive backbone the guidelines demand. The authors conclude that the new ERS guidance gives health services a benchmark for improving care, and perhaps most importantly, a lever to argue for faster access to the respiratory physiotherapy that this case shows can matter as much as any antibiotic.

Subject of Research: Real-world management of difficult bronchiectasis exacerbations guided by the 2025 European Respiratory Society guidelines

Article Title: Real‐World Management of Difficult Exacerbations of Bronchiectasis: A Case Study to Illustrate How Guidelines Can Support Best Practice

Article References: Bianca, H., Toby, C., Anand, S., & Paul, M. (2026). Real‐World Management of Difficult Exacerbations of Bronchiectasis: A Case Study to Illustrate How Guidelines Can Support Best Practice. Clinical Case Reports, 14(10), Article e73566. https://doi.org/10.1002/ccr3.73566

Image Credits: AI Generated

DOI: 10.1002/ccr3.73566

Keywords: bronchiectasis, exacerbations, ERS guidelines, Pseudomonas aeruginosa, airway clearance techniques, virtual ward, antibiotics, azithromycin, respiratory physiotherapy, mucociliary clearance, inhaled antibiotics, pulmonary rehabilitation